Management dilemma in choosing evolving treatments in neutropenic septic shock.

How does a physician decide to use a recently FDA-approved life-saving device in a desperately ill child in which little prior clinical experience is available? This report presents a pediatric patient with neutropenic septic shock and multiorgan failure (MOF) with a 95% chance of death and the avai...

Descripción completa

Detalles Bibliográficos
Publicado en:Pediatric Nephrology Vol. 40; no. 11; pp. 3577 - 3584
Autores principales: Humes, H. David, Luckritz, Kera, Gorga, Stephen, Plomaritas, Katie, Hoatlin, Sara, Humes, Michael, Yessayan, Lenar
Formato: case study pictorial tables/charts Journal Article
Publicado: Springer Nature Nov2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188353541&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 188353541
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0931041X
        EF1
      jtl: Pediatric Nephrology
      issn: 0931041X
      maglogo: N
    pubinfo:
      dt: Nov2025
      vid: 40
      iid: 11
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        188353541
        186044768
        188353541
        188353541
        10.1007/s00467-025-06798-y
        188353541
      ppf: 3577
      ppct: 7
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Management dilemma in choosing evolving treatments in neutropenic septic shock.
      aug:
        au:
          Humes, H. David
          Luckritz, Kera
          Gorga, Stephen
          Plomaritas, Katie
          Hoatlin, Sara
          Humes, Michael
          Yessayan, Lenar
        affil: https://ror.org/00jmfr291 Department of Internal Medicine (Nephrology), University of Michigan, Ann Arbor, MI, USA
      sug:
        subj:
          Neutropenia Therapy
          Shock, Septic Therapy
          Multiple Organ Dysfunction Syndrome Therapy
          Cell Therapy
          Decision Making, Clinical
          Multiple Organ Dysfunction Syndrome Immunology
          Neutropenia Complications
          Shock, Septic Immunology
          Immunologic Factors
          Male
          Child
          Kidney Transplantation
          Renal Insufficiency, Chronic Surgery
          Induction Chemotherapy
          Magnetic Resonance Imaging
          Lymphoma, B-Cell Diagnosis
          Positron-Emission Tomography
          Disseminated Intravascular Coagulation Diagnosis
          Shock, Septic Diagnosis
          Multiple Organ Dysfunction Syndrome Diagnosis
          Treatment Outcomes
          Critically Ill Patients
          Shock, Septic Etiology
          Multiple Organ Dysfunction Syndrome Etiology
          Neutrophils Immunology
          Child: 6-12 years
          Male
      ab: How does a physician decide to use a recently FDA-approved life-saving device in a desperately ill child in which little prior clinical experience is available? This report presents a pediatric patient with neutropenic septic shock and multiorgan failure (MOF) with a 95% chance of death and the availability of a therapeutic device with a completely new approach to treat sepsis. This device, called the selective cytopheretic device (SCD), is a first-in-class autologous immune cell directed therapy. The SCD, when integrated into an extracorporeal blood circuit, has been shown to bind activated neutrophils and monocytes. With a simple pharmacologic maneuver within the device, the bound cells in real time are immunomodulated from a highly pro-inflammatory state to a less inflammatory phenotype. These transformed cells are then released back into the systemic circulation thereby tempering the systemic hyperinflammatory disorder. Since this cell directed therapy focuses on neutrophils, the processing of these cells in a neutropenic state may be a substantive risk resulting in further immunosuppression. On the other hand, the immunomodulation of the circulating neutrophils and monocytes, although sparse, may be beneficial to disrupt the dysregulated inflammatory state responsible for ongoing tissue damage and organ dysfunction. Prior clinical SCD trials excluded patients with neutropenia so that no prior clinical experience was available to make a difficult decision. This report presents the way the medical team approached these issues and made a therapeutic plan that resulted in a positive clinical outcome for the patient.
      pubtype: Academic Journal
      doctype:
        case study
        pictorial
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N